Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gordon

Showing results (1491-1500 of 1,800) with videos related to

Pageof 180
Sort By:
Rheumatology (Oxford, England)|April 19, 2002
Immune responses to native beta(2)-glycoprotein I in patients with systemic lupus erythematosus and the antiphospholipid syndromeM L Davies, S P Young, K Welsh, et al.
Journal Francais D'Ophtalmologie|December 22, 2018
The effect of light and outdoor activity in natural lighting on the progression of myopia in childrenH Sánchez-Tocino, A Villanueva Gómez, C Gordon Bolaños, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 22, 2014
Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter studyNezam H Afdhal, Bruce R Bacon, Keyur Patel, et al.
Alimentary Pharmacology & Therapeutics|February 18, 2022
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current dataYoung-Suk Lim, Wai-Kay Seto, Masayuki Kurosaki, et al.
Antiviral Therapy|October 11, 2012
A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patientsEric J Lawitz, John M Hill, Thomas Marbury, et al.
Alimentary Pharmacology & Therapeutics|September 20, 2016
Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013P R Spradling, J Xing, L B Rupp, et al.
IJID Regions|July 21, 2025
Real-world effectiveness, safety, and health-related quality of life in people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide-12-month results of the BICSTaR French cohortLaurent Hocqueloux, Fabrice Bonnet, Claudine Duvivier, et al.
Australian Critical Care : Official Journal of the Confederation of Australian Critical Care Nurses|May 18, 2013
Clinical components and associated behavioural aspects of a complex healthcare intervention: multi-methods study of selective decontamination of the digestive tract in critical careStephan U Dombrowski, Maria E Prior, Eilidh Duncan, et al.
Scientific Reports|June 11, 2021
Elovanoids downregulate SARS-CoV-2 cell-entry, canonical mediators and enhance protective signaling in human alveolar cellsJorgelina M Calandria, Surjyadipta Bhattacharjee, Nicholas J Maness, et al.
The Journal of Rheumatology|February 24, 2000
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International ComparisonD D Gladman, C H Goldsmith, M B Urowitz, et al.
Pageof 180

Showing results (1491-1500 of 1,800) with videos related to

Sort By:
Pageof 180
Rheumatology (Oxford, England)|April 19, 2002
Immune responses to native beta(2)-glycoprotein I in patients with systemic lupus erythematosus and the antiphospholipid syndromeM L Davies, S P Young, K Welsh, et al.
Journal Francais D'Ophtalmologie|December 22, 2018
The effect of light and outdoor activity in natural lighting on the progression of myopia in childrenH Sánchez-Tocino, A Villanueva Gómez, C Gordon Bolaños, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 22, 2014
Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter studyNezam H Afdhal, Bruce R Bacon, Keyur Patel, et al.
Alimentary Pharmacology & Therapeutics|February 18, 2022
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current dataYoung-Suk Lim, Wai-Kay Seto, Masayuki Kurosaki, et al.
Antiviral Therapy|October 11, 2012
A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patientsEric J Lawitz, John M Hill, Thomas Marbury, et al.
Alimentary Pharmacology & Therapeutics|September 20, 2016
Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013P R Spradling, J Xing, L B Rupp, et al.
IJID Regions|July 21, 2025
Real-world effectiveness, safety, and health-related quality of life in people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide-12-month results of the BICSTaR French cohortLaurent Hocqueloux, Fabrice Bonnet, Claudine Duvivier, et al.
Australian Critical Care : Official Journal of the Confederation of Australian Critical Care Nurses|May 18, 2013
Clinical components and associated behavioural aspects of a complex healthcare intervention: multi-methods study of selective decontamination of the digestive tract in critical careStephan U Dombrowski, Maria E Prior, Eilidh Duncan, et al.
Scientific Reports|June 11, 2021
Elovanoids downregulate SARS-CoV-2 cell-entry, canonical mediators and enhance protective signaling in human alveolar cellsJorgelina M Calandria, Surjyadipta Bhattacharjee, Nicholas J Maness, et al.
The Journal of Rheumatology|February 24, 2000
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International ComparisonD D Gladman, C H Goldsmith, M B Urowitz, et al.
Pageof 180